Arvinas (ARVN) Total Non-Current Liabilities (2017 - 2018)
Arvinas' (ARVN) quarterly Total Non-Current Liabilities came in at $62.5 million in Q4 2018, down 6.14% year-on-year from $66.6 million in Q4 2017, and down 6.14% quarter-over-quarter from $66.6 million in Q4 2017.
Arvinas (ARVN) Total Non-Current Liabilities (2017 - 2018) Analysis & Trends
Arvinas' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $62.5 million for Q4 2018.
- On a quarterly basis, Total Non-Current Liabilities fell 6.14% year-over-year to $62.5 million in Q4 2018; TTM through Dec 2018 was $62.5 million, a 6.14% decrease from a year earlier, with the FY2018 full-year figure at $62.5 million, down 6.14% from the prior year.
- Total Non-Current Liabilities declined to $62.5 million in Q4 2018 per ARVN's latest filing, from $66.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $66.6 million in Q4 2017 and bottomed at $62.5 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 62.46 Mn |
| Dec 31, 2017 | 66.55 Mn |